Generic AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL INN entry, drug patent and freedom to operate

Sponsor	Phase
Daiichi Sankyo, Inc.	Phase 3
Daiichi Sankyo Inc.	Phase 3
Daiichi Sankyo Inc.	Phase 4

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Piramal	OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE	amlodipine besylate; hydrochlorothiazide; olmesartan medoxomil	TABLET;ORAL	210718-001	May 14, 2025	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Ph Health	OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE	amlodipine besylate; hydrochlorothiazide; olmesartan medoxomil	TABLET;ORAL	206137-002	Oct 26, 2016	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Cosette	TRIBENZOR	amlodipine besylate; hydrochlorothiazide; olmesartan medoxomil	TABLET;ORAL	200175-005	Jul 23, 2010	AB	RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Cosette	TRIBENZOR	amlodipine besylate; hydrochlorothiazide; olmesartan medoxomil	TABLET;ORAL	200175-001	Jul 23, 2010	5,616,599*PED	⤷ Start Trial
Cosette	TRIBENZOR	amlodipine besylate; hydrochlorothiazide; olmesartan medoxomil	TABLET;ORAL	200175-002	Jul 23, 2010	5,616,599*PED	⤷ Start Trial
Cosette	TRIBENZOR	amlodipine besylate; hydrochlorothiazide; olmesartan medoxomil	TABLET;ORAL	200175-005	Jul 23, 2010	5,616,599*PED	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Last updated: February 15, 2026

What Are the Current Market Sizes and Growth Rates?

The global antihypertensive drug market encompasses a combined therapeutic scope of approximately $40 billion as of 2022, with a compound annual growth rate (CAGR) around 3.5% projected through 2028. The segment containing amlodipine besylate, hydrochlorothiazide, and olmesartan medoxomil accounts for roughly 60% of this market, driven by the high prevalence of hypertension worldwide.

Key market size estimates:

Amlodipine (all formulations): Estimated at $8.5 billion in global sales 2022, growing at approximately 2.8% CAGR.
Hydrochlorothiazide: Estimated sales of $4.2 billion in 2022, with a CAGR near 2.3%.
Olmesartan medoxomil: Estimated at $1.5 billion in 2022, with a CAGR around 3.2%.

Growth is primarily fueled by the rising incidence of hypertension in emerging markets, improved access to healthcare, and the transition from branded to generic formulations.

How Do Patent Expirations Impact Market Revenue and Competition?

Patent expirations influence market dynamics significantly for these medications.

Amlodipine: The patent expired in the U.S. in 2010. This led to a surge in generic competition, reducing prices by approximately 80% within three years.
Hydrochlorothiazide: Off-patent since the 1980s, with multiple generics available, exerting downward pressure on prices and profit margins.
Olmesartan medoxomil: Patent protection expired in 2019. The influx of generics has led to a price decline of approximately 45% compared to branded prices.

Market share shifts toward generic manufacturers have resulted in a decrease in revenue for original developers but increased accessibility and volume sales across markets.

What Are the Major Regional Drivers and Market Penetration?

North America:

Dominates the market; approximately 45% of global sales.
High penetration of branded drugs until patent expirations.
Increased adoption of generics has led to lower prices but higher volume.

Europe:

Accounts for around 25% of sales.
Strict regulation and preference for generics have driven price competition.
Adherence to national guidelines promotes use of combination therapies.

Asia-Pacific:

Fastest-growing region; CAGR over 6% projected.
Increases driven by rising hypertension prevalence, urbanization, and healthcare access.
Local manufacturers produce cost-effective generics, gaining market share.

Emerging markets: Expected to expand due to increased hypertension awareness, healthcare infrastructure investments, and government initiatives targeting non-communicable diseases.

How Is Competitive Pressure Evolving?

The landscape features tight competition among generic manufacturers, including:

Major players: Teva Pharmaceuticals, Sandoz, Mylan, and Hikma.
Market entry barriers: Regulatory approval processes, manufacturing capacity, and pricing strategies.
Innovative strategies: Fixed-dose combination drugs and biosimilars are increasingly introduced to differentiate products.

Brand-name incumbents have reduced R&D investments, focusing instead on patent strategies and market share defense.

What Are the Regulatory and Policy Factors Affecting Market Trajectory?

Patent laws: Variations across jurisdictions influence timing for generic entry.
Pricing regulations: Governments in Canada, the UK, and parts of Asia negotiate drug prices, affecting revenue forecasts.
Prescription guidelines: Emphasize cost-effective therapies, favoring generic and combination drugs which include these components.
Reimbursement policies: Expand coverage for combination therapies, promoting volume growth.

Recent policies in the U.S. aim to curb drug prices, putting additional pressure on profit margins for both brand and generic manufacturers.

What Is the Future Financial Outlook?

Revenue stability: While patent expiration curtails branded revenue in mature markets, volume growth in emerging regions offsets this decline.
Profit margins: Decline in prices due to generics opposes increased sales volume, resulting in relatively stable gross margins.
Innovation potential: New fixed-dose combinations and formulations could generate premium prices, especially in markets adopting personalized medicine approaches.
Market expansion opportunities: Focus on hypertension comorbidities, including kidney disease and cardiovascular risk management.

Projections suggest a compound annual growth rate in overall antihypertensive segment of 3%–4% through 2030, with specific opportunities for combination therapies containing these drugs.

Key Takeaways

The combined market for amlodipine, hydrochlorothiazide, and olmesartan is approximately $14.2 billion, with growth driven mainly by emerging markets.
Patent expirations have significantly increased competition, with generics dominating sales.
Regional penetration varies: North America leads in revenue, while Asia-Pacific exhibits the highest growth potential.
Regulatory policies and healthcare reforms influence both pricing strategies and market expansion.
Future revenues depend on market penetration, pricing strategies, and successful development of innovative fixed-dose combinations.

FAQs

1. How will patent expirations affect the revenue potential of these drugs?
Patent expirations typically lead to a sharp decline in branded drug revenues due to increased generic competition, but volume sales often rise. The overall revenue impact depends on market penetration levels and the ability of brand incumbents to maintain market share through alternatives like fixed-dose combinations.

2. Which regions offer the highest growth opportunities?
Asia-Pacific currently exhibits the highest CAGR, driven by increasing hypertension prevalence, urbanization, and healthcare infrastructure improvements. Emerging markets in Latin America and Africa also present promising opportunities.

3. Are fixed-dose combination drugs affecting market dynamics?
Yes. Fixed-dose combinations that include amlodipine, hydrochlorothiazide, and olmesartan can improve adherence and therapeutic outcomes, enabling premium pricing and market differentiation.

4. How do regulatory policies impact the availability of generics?
Stringent regulatory approval processes and patent linkage systems can delay generic entry, maintaining higher prices longer. Conversely, relaxed policies accelerate generics' market entry, reducing prices.

5. What is the outlook for innovative formulations like long-acting or sustained-release versions?
Development of long-acting formulations can command higher prices and improve patient compliance, creating new revenue streams amid generic competition.

Sources:
[1] Market Research Future, "Antihypertensive Drugs Market," 2022.
[2] IQVIA, "Global Pharmaceutical Market Report," 2022.
[3] EvaluatePharma, "Top Selling Drugs," 2022.
[4] U.S. Food and Drug Administration, "Generic Drugs," 2022.

US Patents:	0
Tradenames:	2
Applicants:	8
NDAs:	8
Finished Product Suppliers / Packagers:	9
Clinical Trials:	4
DailyMed Link:	AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL at DailyMed

Drug Class	Angiotensin 2 Receptor Blocker Calcium Channel Blocker Dihydropyridine Calcium Channel Blocker Thiazide Diuretic
Mechanism of Action	Angiotensin 2 Receptor Antagonists Calcium Channel Antagonists Cytochrome P450 3A Inhibitors
Physiological Effect	Increased Diuresis

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - Generic Drug Details

What are the generic drug sources for amlodipine besylate; hydrochlorothiazide; olmesartan medoxomil and what is the scope of freedom to operate?

Summary for AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

Recent Clinical Trials for AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

Pharmacology for AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

Anatomical Therapeutic Chemical (ATC) Classes for AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

US Patents and Regulatory Information for AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

Expired US Patents for AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

Market Dynamics and Financial Trajectory for Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil